Why the study?
What are the appropriate NSAID treatment strategies based on different combinations of gastrointestinal and cardiovascular risks?
What are the appropriate NSAID treatment strategies based on different combinations of gastrointestinal and cardiovascular risks?
This consensus recommendation provides a framework for selecting NSAID therapy based on a patient's combined cardiovascular and gastrointestinal risk profile, highlighting naproxen as the preferred choice in high CV risk.
No takes yet. Share an insight, caveat, or question.
Offers actionable guidance for NSAID selection by combined CV-GI risk; reinforces Level 1 consensus on tailored therapy.
Chan et al. (2008) studied Patients requiring Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (n=19). NSAID treatment strategies (naproxen, nonselective NSAIDs, coxibs, with or without PPI/misoprostol) was evaluated on Appropriateness of NSAID options (score 7-9 by ≥80% of panelists). An expert panel concluded that naproxen is preferred for patients with high cardiovascular risk, while gastrointestinal risk dictates the need for PPI/misoprostol or coxibs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: